Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | BCKDK | O14874 | 1/20 | 0.30 |
| ▸ | RPA1 | P27694 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3113064 | 0.83 | ALDH1A1 (0.43) | — | |
| SCHEMBL1267416 | 0.81 | ALDH1A1 (0.36) | — | |
| SCHEMBL1266759 | 0.81 | BCKDK (0.36) | BCKDKRPA1 | |
| SCHEMBL3114743 | 0.79 | TYK2 (0.34) | MAPK14MAPK13MAPK12MAPK11PDE4B | |
| SCHEMBL4562849 | 0.79 | TYK2 (0.34) | MAPK14MAPK13MAPK12MAPK11PDE4B | |
| SCHEMBL3118759 | 0.79 | TYK2 (0.34) | MAPK14MAPK13MAPK12MAPK11PDE4B | |
| SCHEMBL3116038 | 0.76 | RAB9A (0.45) | — | |
| SCHEMBL3115823 | 0.76 | RAB9A (0.45) | — | |
| SCHEMBL1266124 | 0.76 | NOTUM (0.39) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12895320 | 0.74 | GPR35 (0.35) | BCKDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-15 | — | — | US | claimed |
| EP-2099805-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB Pharma S.A. (BE) | 2009-09-16 | — | — | EP | claimed |
| WO-2008064829-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-06-05 | — | — | WO | claimed |
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-15 | — | — | US | disclosed |
| EP-2099805-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB Pharma S.A. (BE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064829-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | AASDHPPT, PTMS, TPMT | MAPK14 3742/4885MAPK13 3361/4885MAPK12 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.